Chen Qingfeng, Wang Jiaxu, Liu Wai Nam, Zhao Yue
Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Stem Cell and Regenerative Biology, Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore.
Transl Oncol. 2019 Jul;12(7):987-995. doi: 10.1016/j.tranon.2019.04.020. Epub 2019 May 20.
Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients' tumor and immune system, and predict patients' responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo.
癌症免疫疗法是一种恢复并刺激人体免疫系统以抑制癌症生长或根除癌症的治疗方法。它是最新的全身治疗方法之一,已被批准用于治疗不同类型癌症的患者。然而,临床缓解率并不理想,观察到的反应大多是患者的部分缓解。尽管新型癌症免疫疗法不断改进和涌现,但迫切需要建立一个强大的平台来评估临床前药物的疗效和安全性,模拟患者肿瘤与免疫系统之间的相互作用,并预测患者对治疗的反应。在本综述中,我们总结了现有免疫肿瘤学检测平台的优缺点,特别是用于筛选癌症免疫疗法药物的人源化小鼠模型。此外,还讨论了将人源化小鼠模型用作筛选工具的各种新趋势和进展。值得注意的是,人源化小鼠模型还可用于进一步开发治疗癌症的个性化精准药物。总体而言,这些突出了人源化小鼠模型作为体内筛选下一代癌症免疫疗法重要平台的意义。